Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CytoDyn In Damage-Control Mode (Again) With Clinical Holds For Leronlimab

Executive Summary

Troubled leronlimab is placed on partial clinical hold in HIV, full clinical hold in COVID-19. While searching for a new CEO, CytoDyn tries to reassure investors about its business plan going forward.

You may also be interested in...



PureTech’s Failure Leaves Long COVID Treatment Hopes Looking Thin

PureTech’s LYT-100 has failed to show benefit over placebo in long COVID, and raised doubts about how treatable the condition is – in contrast to the drug’s other potential use in idiopathic pulmonary fibrosis.

EU Laws On Medicines Supply To Northern Ireland Move Closer

Draft legislation that would avoid post-Brexit regulatory problems for medicines moving between Great Britain and Northern Ireland is on course for formal adoption.

CytoDyn’s Promotion Of Investigational Drug Leronlimab Once Again Rebuked By US FDA

OPDP warning letter objects to video interview in which CytoDyn's then CEO touts use of the investigational drug for COVID-19. The exec says he is ‘making up numbers’ but if the pattern continues there will be ‘the most fantastic results’ anybody could ever imagine.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel